Healthcare Technology

GLP-1 is restructuring every healthcare platform's business model simultaneously.

GLP-1 dynamics are reshaping revenue architecture across the sector: Hims & Hers absorbed a $33M write-down to pivot from compounded to branded Wegovy and now processes over 100,000 new weight-loss subscribers per month; GoodRx processed roughly one-third of all Wegovy Pill transactions in the first two months post-launch while Pharma Direct grew 82% year-over-year in Q1 2026; HealthEquity launched a GLP-1 marketplace targeting a self-described market opportunity of more than $100 billion. No other sector theme is simultaneously driving M&A, product launches, channel strategy, and pricing model changes across this many companies.

MFN pricing freeze is the binding near-term constraint on pharma marketing platforms.

Most Favored Nation pricing agreements signed by 16 of the top 20 pharma manufacturers in late December 2025 and early January 2026 created a sector-wide contracted-revenue freeze that management teams at Doximity, OptimizeRx, and Veeva each cited independently. OptimizeRx lowered FY2026 revenue guidance to $95-100M and reported contracted revenue running 15-20% below prior-year levels; Doximity guided FY2027 to 4% growth as its slowest in recent history; Veeva embedded an explicit macro carve-out in FY2027 guidance. The disruption is compounding because it shortens contract durations from 6-12 months to quarterly pulses, structurally reducing forward revenue visibility even after individual negotiations resolve.

Agentic AI is crossing from product language to priced commercial offering.

Veeva launched Falcon, a per-document and per-case agentic labor platform targeting clinical document management and pharmacovigilance, with the CEO taking direct oversight — the first consumption-priced labor-substitution product in Veeva's history. Doximity launched AI Search commercially in late April 2026, closing initial deals with top-20 pharma manufacturers within weeks of going to market. Amwell explicitly repositioned from generative AI features to infrastructure for agentic AI deployment, while HealthEquity characterized AI as an 'earnings engine' generating a $17M year-over-year service cost reduction in Q4 FY2026. The language threshold crossed this cycle is from 'we are investing in AI' to 'AI is reducing our cost structure and generating new revenue.'

Platform consolidation is accelerating as health systems eliminate point-solution sprawl.

Doximity contracted 140 health systems on its AI suite in roughly two quarters, a pace twice as fast as its telehealth product achieved over two years, driven by hospital security mandates pushing HIPAA-compliant consolidation. Omnicell is capturing share from a primary incumbent facing a Class II FDA recall as health systems reassess single-vendor medication management platforms. Amwell secured 15-plus payer renewals including a three-year Elevance deal and reports its pipeline is entirely composed of its unified platform with no point-solution components. The common dynamic: health system IT departments lack the integration capacity to manage multi-vendor sprawl, creating a structural purchasing preference for horizontal platform operators.